Phase II study evaluated erlotinib plus bevacizumab ‘a humanised monoclonal antibody against VEGF that is Food and Drug Administration (FDA)-approved for recurrent GBM’ [40] was conducted on patients with rGBM [41]. The gene discussed is VEGFA; the disease is glioblastoma.